copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Callio Therapeutics | Multi-payload antibody-drug conjugates Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187 0 million Series A financing round
Callio Therapeutics Launches with US$187 Million Series A to . . . SEATTLE and SINGAPORE, March 3, 2025 — Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187 0 million Series A financing round
Callio gets in on the dual payload action | ApexOnco . . . Singapore-headquartered Hummingbird will continue developing its monoclonal antibodies, HMBD-001 and HMBD-002, and also retains rights to its ADC technology for non-oncology uses, a spokesperson for Seattle-based Callio told ApexOnco
Newly Launched Seattle Cancer Therapy Startup Callio . . . Biotech-focused investment firm Frazier Life Sciences has launched Callio Therapeutics, a cancer treatment startup with headquarters in Seattle and Singapore Frazier led a $187 million Series A round to get the company started
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs Hummingbird granted Callio an exclusive license to use its “multi-payload” ADC technology in oncology In return, Hummingbird received equity in Callio and could get additional milestone payments Headquartered in Seattle and Singapore, Callio was launched by Frazier Life Sciences